A holistic pharmaceutical exposure and experience within the group-level while answering to two more layers of major groups (1 conglomerate, 1 GLIC) which struggles to balance business performance and political lobbying.The good thingsIntegrated pharmaceutical company providing immense exposure in multiple areas, namely logistics, manufacturing, commercialisation, regulatory affairs of the pharmaceutical industry.
The challengesManagement and corporate direction is highly influenced by government political headwinds due to its GLC nature. The company has two layers of shareholders to answer to, causing several miscommunication issues, ultimately leading to lasting consequences.